Total Payments
$226,272
2024 Payments
$49,182
Companies
14
Transactions
149
Medicare Patients
323
Medicare Billing
$41,816
Payment Breakdown by Category
Consulting$169,400 (74.9%)
Other$34,882 (15.4%)
Travel$19,275 (8.5%)
Food & Beverage$2,716 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $169,400 | 63 | 74.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $34,425 | 6 | 15.2% |
| Travel and Lodging | $19,275 | 30 | 8.5% |
| Food and Beverage | $2,716 | 49 | 1.2% |
| Grant | $457.05 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $94,735 | 33 | $0 (2024) |
| Merck Sharp & Dohme LLC | $34,352 | 29 | $0 (2024) |
| Xellia Pharmaceuticals | $28,622 | 15 | $0 (2023) |
| Shionogi Inc | $27,087 | 34 | $0 (2023) |
| ABBVIE INC. | $14,147 | 15 | $0 (2024) |
| Genentech, Inc. | $10,800 | 3 | $0 (2021) |
| Janssen Global Services, LLC | $4,320 | 1 | $0 (2022) |
| Becton, Dickinson and Company | $4,113 | 3 | $0 (2024) |
| PFIZER INC. | $3,964 | 6 | $0 (2017) |
| Ferring Pharmaceuticals Inc. | $2,390 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $49,182 | 23 | GlaxoSmithKline, LLC. ($35,036) |
| 2023 | $53,881 | 20 | GlaxoSmithKline, LLC. ($33,256) |
| 2022 | $32,026 | 20 | GlaxoSmithKline, LLC. ($24,567) |
| 2021 | $18,601 | 8 | Genentech, Inc. ($10,800) |
| 2020 | $8,444 | 5 | Merck Sharp & Dohme Corporation ($4,875) |
| 2019 | $10,070 | 13 | Xellia Pharmaceuticals ($4,726) |
| 2018 | $40,293 | 29 | Xellia Pharmaceuticals ($23,006) |
| 2017 | $13,777 | 31 | Merck Sharp & Dohme Corporation ($7,108) |
All Payment Transactions
149 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,301.50 | General |
| 12/12/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 12/03/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $4,550.00 | General |
| 11/15/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 11/15/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $10.36 | General |
| 11/05/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $2,362.50 | General |
| 10/28/2024 | Melinta Therapeutics, LLC | Vabomere (Drug), Rezzayo | Food and Beverage | In-kind items and services | $28.92 | General |
| Category: ANTIBIOTICS | ||||||
| 10/16/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $45.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/16/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $22.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/16/2024 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.74 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/15/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $77.71 | General |
| 09/05/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $1,027.76 | General |
| 08/16/2024 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| 06/14/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $6,175.00 | General |
| 06/14/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $617.50 | General |
| 06/14/2024 | GlaxoSmithKline, LLC. | — | Grant | Cash or cash equivalent | $457.05 | General |
| 06/06/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 04/29/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $1,395.00 | General |
| 02/28/2024 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $7,054.13 | General |
| 02/02/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 01/11/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $5,000.00 | General |
| 01/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $430.87 | General |
| 01/11/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $388.91 | General |
| 12/19/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Consulting Fee | Cash or cash equivalent | $2,390.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/08/2023 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,900.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 73 | 92 | $73,097 | $8,276 |
| 2022 | 3 | 94 | 128 | $106,190 | $13,978 |
| 2021 | 3 | 59 | 73 | $40,590 | $7,059 |
| 2020 | 4 | 97 | 143 | $38,479 | $12,503 |
Total Patients
323
Total Services
436
Medicare Billing
$41,816
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 27 | 27 | $33,455 | $3,558 | 10.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 42 | $22,245 | $2,503 | 11.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 23 | $17,397 | $2,216 | 12.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 43 | 44 | $55,220 | $7,336 | 13.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 34 | 66 | $42,834 | $5,531 | 12.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 17 | 18 | $8,136 | $1,111 | 13.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 14 | 15 | $17,936 | $2,593 | 14.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 28 | 41 | $13,689 | $2,509 | 18.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 17 | 17 | $8,965 | $1,957 | 21.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 39 | 67 | $12,733 | $4,057 | 31.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 17 | 35 | $10,031 | $3,015 | 30.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 26 | 26 | $8,554 | $2,990 | 34.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 15 | $7,161 | $2,442 | 34.1% |
About Dr. Keith Kaye, M.D
Dr. Keith Kaye, M.D is a Internal Medicine healthcare provider based in Ann Arbor, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2006. The National Provider Identifier (NPI) number assigned to this provider is 1083777858.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Keith Kaye, M.D has received a total of $226,272 in payments from pharmaceutical and medical device companies, with $49,182 received in 2024. These payments were reported across 149 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($169,400).
As a Medicare-enrolled provider, Kaye has provided services to 323 Medicare beneficiaries, totaling 436 services with total Medicare billing of $41,816. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease, Infectious Disease
- Location Ann Arbor, MI
- Active Since 12/19/2006
- Last Updated 04/30/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1083777858
Products in Payments
- Fetroja (Drug) $6,257
- ZERBAXA (Drug) $5,488
- Vancomycin (Drug) $3,614
- TEFLARO (Drug) $2,615
- REBYOTA (Biological) $2,390
- MK-7655A (Drug) $2,275
- RECARBRIO (Drug) $2,100
- ACCELERATE PHENO (Device) $1,500
- AVYCAZ (Drug) $500.91
- Vabomere (Drug) $92.30
- NUZYRA (Drug) $71.28
- Kimyrsa (Drug) $34.99
- VABOMERE (Drug) $28.79
- ORBACTIV (Drug) $14.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Ann Arbor
Dr. Marschall Runge, Md, MD
Internal Medicine — Payments: $2.3M
Internal Medicine $2.3M
Terry Smith, M.d, M.D
Internal Medicine — Payments: $2.1M
Internal Medicine $2.1M
Harry Erba, Md, MD
Internal Medicine — Payments: $1.8M
Internal Medicine $1.8M
Dr. Dinesh Khanna, M.d, M.D
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Alexander Yevzlin, Md, MD
Internal Medicine — Payments: $1.2M
Internal Medicine $1.2M
Vallerie Mclaughlin, Md, MD
Internal Medicine — Payments: $1.1M
Internal Medicine $1.1M